Author(s):
Bagwan Md. Aakif, Manoj Mahajan, Aman B. Upaganlawar, Swati Jadhav, Chandrashekhar Upasani
Email(s):
amanrxy@gmail.com
DOI:
10.52711/2231-5675.2025.00009 
Address:
Bagwan Md. Aakif, Manoj Mahajan, Aman B. Upaganlawar*, Swati Jadhav, Chandrashekhar Upasani
Department of Pharmacology at SNJB’s Shriman Suresh Dada Jain College of Pharmacy, Chandwad - Nashik. 423101, Maharashtra.
*Corresponding Author
Published In:
Volume - 15,
Issue - 1,
Year - 2025
ABSTRACT:
A wide range of pharmaceutical medications have been employed to facilitate the blockage of the neurohumoral system that is implicated in the pathogenesis of congestive heart failure (CHF). An often-used antiarrhythmic medication is amiodarone. Treatment for persistent ventricular tachycardia, ventricular fibrillation, and class III atrial fibrillation are indicated. There is curiosity about metoprolol, which is a selective ß1-adrenergic receptor blocker. Myocardial infarction, atrial fibrillation/edema, Heart failure (HF), and hypertension are among the conditions for which the FDA has approved treatments. Among the most common reasons for adverse drug reaction (ADR) is drug exposure, and we find that polypharmacy contributes to the higher prevalence of this syndrome among the elderly. Drug interactions involving amiodarone have been documented. mostly blocks CYP2C8 and CYP3A4, with CYP1A2, CYP2C19, and CYP2D6 being slightly blocked as well. The finding that using amiodarone was linked to greater amounts of a-OH-metoprolol was unexpected. The existing literature indicates that the concentration of a-OH-metoprolol will likely decrease with moderate and strong CYP2D6 inhibitors. Cardiovascular Pharmacogenomics focuses on the development and selection of cardiovascular drugs to increase therapeutic efficacy and reduce toxicity. The purpose of this article is to investigate the pharmacogenetic and drug-drug interactions between amiodarone and metoprolol and their side effects.
Cite this article:
Bagwan Md. Aakif, Manoj Mahajan, Aman B. Upaganlawar, Swati Jadhav, Chandrashekhar Upasani. Pharmacogenomics and Drug-Drug Interaction between Amiodarone and Metoprolol. Asian Journal of Pharmaceutical Analysis. 2025;15(1):51-6. doi: 10.52711/2231-5675.2025.00009
Cite(Electronic):
Bagwan Md. Aakif, Manoj Mahajan, Aman B. Upaganlawar, Swati Jadhav, Chandrashekhar Upasani. Pharmacogenomics and Drug-Drug Interaction between Amiodarone and Metoprolol. Asian Journal of Pharmaceutical Analysis. 2025;15(1):51-6. doi: 10.52711/2231-5675.2025.00009 Available on: https://ajpaonline.com/AbstractView.aspx?PID=2025-15-1-9
REFERENCES:
1. Knuiman M, Briffa T, Divitini M, et al. A cohort study examination of established and emerging risk factors for atrial fibrillation: the Busselton Health Study. Eur J Epidemiol. 2014; 29:181–90.
2. Kirchhof P, Benussi S, Kotecha D, et al. 2016 ESC guidelines for the management of atrial fibrillation developed in collaboration with EACTS [published correction appears in Rev Esp Cardiol (Engl Ed). 2017 Nov; 70(11):1031]. Rev Esp Cardiol (Engl Ed). 2017; 70:50.
3. Rogers PA, Bernard ML, Madias C, et al. Current evidence-based understanding of the epidemiology, prevention, and treatment of atrial fibrillation. Curr Probl Cardiol. 2018; 43:241–83.
4. Andrade JG, Verma A, Mitchell LB, et al. 2018 focused update of the Canadian Cardiovascular Society Guidelines for the management of atrial fibrillation. Can J Cardiol. 2018; 34:1371–92.
5. Jose A, Chandran L, Zachariah SM. Pharmacogenomics: the right drug to the right person. J Clin Med Res. 2019 Oct; 1(4):191-4.
6. Frohlich H, Zhao J, Täger T, Cebola R, Schellberg D, Katus HA, Grundtvig M, Hole T, Atar D, Agewall S, Frankenstein L. Carvedilol Compared With Metoprolol Succinate in the Treatment and Prognosis of Patients With Stable Chronic Heart Failure: Carvedilol or Metoprolol Evaluation Study. Circ Heart Fail. 2015 Sep; 8(5): 887-96.
7. G. Swapna, B. Pravallika, J. Poojitha. A Review on Drug-drug interaction studies on Amiodarone and Levofloxacin. Res. J. Pharmacology and Pharmacodynamics.2019; 11(4):147-152.
8. Vishakha D. Patel, Hasumati A. Raj, Nirav K. Gheewala. Second Derivative Spectroscopic Method for Simultaneous estimation of Amiodarone Hydrochloride and Ranolazine in synthetic mixture. Asian J. Pharm. Ana. 2016; 6(1):23-30.
9. Patel Vishakha D, Raj Hasumati A, Gheewala Nirav. Pharmacology of Combined Amiodarone Hydrochloride and Ranolazine Therapy in Atrial Fibrillation. Asian J. Res. Pharm. Sci. 2015; 5(4): 234-238.
10. DK Suresh, Vivek B. Ingale, Mangesh S Gavali, Bhaumik N Thakar, Raghvendra Rao NG. A Study on Effect of Amiodarone on the Pharmacokinetics of Oral Hypoglycaemic Agents in Normal Rabbits. Research J. Pharmacology and Pharmacodynamics. 2012; 4(4):221-224.
11. Jyotsna Pandit Khedkar, Sreemoy Kanti Das, Prashant Suresh Salunke, Sandeep Poddar. Amiodarone’s effect on the Pharmacokinetics of Glibenclamide in Healthy and Diabetic Rats. Research Journal of Pharmacy and Technology 2023; 16(3):1134-8
12. Ragni Kumari, Virendra Kumar Sharma. Optimization of the Formulation of Transdermal patches of Amiodarone. Research Journal of Pharmacy and Technology 2023; 16(8):3739-2.
13. T Venkatachalam, V Kishor Kumar, P Kalai Selvi, R Srinivasan, R Mariammal, KG Lalitha. New Spectrophotometric Method Applied to the Simultaneous Determination of Metoprolol Succinate and Hydrochlorthiazide. Asian J. Research Chem. 2010; 3(2):464-467.
14. Praful D. Gangurde, Rutik L. Pandit, Rutik P. Walekar, Prasad B. Chavan, Zahed R. Bashamlool, Priyanka M. Salve, Balaji M. Narwate. Metoprolol succinate sustained release tablet: A review. Asian Journal of Pharmaceutical Research. 2024; 14(1):62-6.
15. WC Pádua-Filho, DP Brasil, HJ Neves, OM Gomes, EA Bocchi. Effects of metoprolol and amiodarone combination on heart rate, myocardial contractility and coronary flow: Study in isolated perfused rat hearts. Exp Clin Cardiol 2004; 9(2):133-137.
16. Molenaar-Kuijsten, L., Van Balen, D. E. M., Beijnen, J. H., Steeghs, N., and Huitema, A. D. R. A review of CYP3A drug-drug interaction studies: Practical guidelines for patients using targeted oral anticancer drugs. Front. Pharmacol. 2021; 12: 670862.
17. Nguyen, T., Liu, X., Abuhashem, W., Bussing, R., and Winterstein, A. G. Quality of evidence supporting major psychotropic drug-drug interaction warnings: A systematic literature review. Pharmacotherapy. 2020; 4: 455–468.
18. Barbera, N., Busardò, F. P., Indorato, F., and Romano, G. The pathogenetic role of adulterants in 5 cases of drug addicts with a fatal outcome. Forensic Sci. Int. 2013; 227: 74–76.
19. Chitra Jose, Monica Antony, Jyothi Goutham Kumar, Maheswari C, Venkatanarayanan R, Sam Johnson Udaya Chander J. Conceptual and Practical Update on Drug-Drug Interactions. Research J. Pharm. and Tech. 2016; 9(1): 60-68.
20. Franceschi A, Tuccori M, Bocci G, Vannozzi F, Di Paolo A, Barbara C, et al. Drug therapeutic failures in emergency department patients. A university hospital experience. Pharmacol Res. 2014; 49: 85–91.
21. Johnell K, Klarin I. The relationship between number of drugs and potential drug-drug interactions in the elderly: A study of over 600,000 elderly patients from the Swedish Prescribed Drug Register. Drug Saf. 2017; 30: 911–8.
22. https://www.biopharmaservices.com/blog/phase-1-drug-drug-interactions-in-trial-research/
23. Ahmad Ainurofiq, Lutvi Ismaya. Pharmacokinetic Drug-Drug Interactions: A Systematic Review of the Cytochrome P450 (CYP) Isoenzyme 3A4. Research Journal of Pharmacy and Technology 2023; 16(6): 3016-4.
24. Nurliana Abd Mutalib, Mohd Amirul Ariffin Mohd Rafi, Normala Abd Latip. Revisiting CYP2C9-Mediated drug-drug Interactions: A Review. Research Journal of Pharmacy and Technology. 2021; 14(11): 6166-2.
25. Jagadeesan M, Manikandan R, Nandamuri Sri Sai Sudha. The Drug-Drug Interactions: Affecting the Rationality of Prescriptions. Research J. Pharm. and Tech 2018; 11(7): 3077-3080.
26. Kawabata M, Yokoyama Y, Sasaki T, et al. Severe iatrogenic bradycardia related to the combined use of beta-blocking agents and sodium channel blockers. Clin Pharmacol. 2015; 7: 29-36.
27. Robert S, Pilon MO, Oussaïd E, Meloche M, et al. Impact of amiodarone use on metoprolol concentrations, α-OH-metoprolol concentrations, metoprolol dosing and heart rate: A cross-sectional study. Pharmacol Res Perspect. 2023 Oct; 11(5): e01137.
28. Meloche M, Leclair G, Jutras M, et al. Leveraging large observational studies to discover genetic determinants of drug concentrations: a proof‐of‐concept study. Clin Transl Sci. 2022; 15(4): 1063‐1073.
29. ukumoto K, Kobayashi T, Tachibana K, et al. Effect of amiodarone on the serum concentration/dose ratio of metoprolol in patients with cardiac arrhythmia. Drug Metab Pharmacokinet. 2016; 21(6): 501‐505.
30. Ohyama K, Nakajima M, Suzuki M, Shimada N, Yamazaki H, Yokoi T. Inhibitory effects of amiodarone and its N‐deethylated metabolite on human cytochrome P450 activities: prediction of in vivo drug interactions. Br J Clin Pharmacol. 2010; 49(3): 244‐253.
31. Ohyama K, Nakajima M, Nakamura S, Shimada N, Yamazaki H, Yokoi T. A significant role of human cytochrome P450 2C8 in amiodarone N‐deethylation: an approach to predict the contribution with relative activity factor. Drug Metab Dispos. 2010; 28(11): 1303‐1310.
32. Wessler JD, Grip LT, Mendell J, Giugliano RP. The P‐glycoprotein transport system and cardiovascular drugs. J Am Coll Cardiol. 2013; 61(25): 2495‐2502.
33. Berger B, Bachmann F, Duthaler U, Krähenbühl S, Haschke M. Cytochrome P450 enzymes involved in metoprolol metabolism and use of metoprolol as a CYP2D6 phenotyping probe drug. Front Pharmacol. 2018; 9:774.
34. Chen WC, Chen WC, Chen CY, et al. Amiodarone use is associated with increased risk of stroke in patients with nonvalvular atrial fibrillation: a nationwide population‐based cohort study. Medicine. 2015; 94(19): e849.
35. Huang CH, Lai YY, Kuo YJ, et al. Amiodarone and risk of liver cirrhosis: a nationwide, population‐based study. Ther Clin Risk Manag. 2019; 15: 103‐112.
36. Goldschlager N, Epstein AE, Naccarelli G, Olshansky B, Singh B. Practical guidelines for clinicians who treat patients with amiodarone. Practice guidelines subcommittee, north American Society of Pacing and Electrophysiology. Arch Intern Med. 2020; 160(12): 1741‐1748.
37. Muthumala A, Drenos F, Elliott PM, et al. Role of beta adrenergic receptor polymorphisms in heart failure: systematic review and meta-analysis. Eur. J. Heart Fail. 2008; 10:3–13.
38. Rathz DA, Brown KM, Kramer LA, et al. Amino acid 49 polymorphisms of the human beta1- adrenergic receptor affect agonist-promoted trafficking. J. Cardiovasc. Pharmacol. 2022; 39:155–60.
39. Johnson JA, Liggett SB. Cardiovascular pharmacogenomics of adrenergic receptor signaling: clinical implications and future directions. Clin. Pharmacol. Ther. 2011; 89: 366–78.
40. Chen L, Meyers D, Javorsky G, et al. Arg389Gly-beta1-adrenergic receptors determine improvement in left ventricular systolic function in nonischemic cardiomyopathy patients with heart failure after chronic treatment with carvedilol. Pharmacogenet. Genomics 2017; 17: 941–49.
41. Liggett SB, Mialet-Perez J, Thaneemit-Chen S, et al. A polymorphism within a conserved beta(1)-adrenergic receptor motif alters cardiac function and beta-blocker response in human heart failure. Proc. Natl. Acad. Sci. USA 2016; 103: 11288–93.
42. Bristow MR, Murphy GA, Krause-Steinrauf H, et al. An alpha2C-adrenergic receptor polymorphism alters the norepinephrine-lowering effects and therapeutic response of the beta-blocker bucindolol in chronic heart failure. Circ. Heart Fail. 2010; 3: 21–28.
43. Liu J, Liu ZQ, Yu BN, et al. Beta1-adrenergic receptor polymorphisms influence the response to metoprolol monotherapy in patients with essential hypertension. Clin. Pharmacol. Ther. 2006; 80: 23–32.
44. Small KM, Wagoner LE, Levin AM, et al. Synergistic polymorphisms of beta1- and alpha2Cadrenergic receptors and the risk of congestive heart failure. N. Engl. J. Med. 2012; 347: 1135–42.
45. Bijl MJ, Visser LE, van Schaik RH, et al. Genetic variation in the CYP2D6 gene is associated with a lower heart rate and blood pressure in beta-blocker users. Clin. Pharmacol. Ther. 2009; 85: 45–50.
46. Liggett SB, Cresci S, Kelly RJ, et al. A GRK5 polymorphism that inhibits beta-adrenergic receptor signaling is protective in heart failure. Nat. Med. 2008; 14: 510–17.
47. Cresci S, Kelly RJ, Cappola TP, et al. Clinical and genetic modifiers of long-term survival in heart failure. J. Am. Coll. Cardiol. 2009; 54: 432–44.
48. Itoh H, Sakaguchi T, Ding WG, et al. Latent genetic backgrounds and molecular pathogenesis in drug-induced long-QT syndrome. Circ. Arrhythm. Electrophysiol. 2009; 2: 511–23.
49. Kaab S, Crawford DC, Sinner MF, et al. A large candidate gene survey identifies the KCNE1 D85N polymorphism as a possible modulator of drug-induced torsades de pointes. Circ. Cardiovasc. Genet. 2012; 5: 91– 99.
50. Jamshidi Y, Nolte IM, Dalageorgou C, et al. Common variation in the NOS1AP gene is associated with drug-induced QT prolongation and ventricular arrhythmia. J. Am. Coll. Cardiol. 2012; 60: 841–50.
51. Narayana SK, Woods DR, Boos CJ: Management of amiodarone-related thyroid problems. Ther Adv Endocrinol Metab. 2011; 2(3): 115-26.
52. Szalowska E, van der Burg B, Man HY, Hendriksen PJ, Peijnenburg AA: Model steatogenic compounds (amiodarone, valproic acid, and tetracycline) alter lipid metabolism by different mechanisms in mouse liver slices. PLoS One. 2014; 9(1): e86795.
53. Song M, Kim YJ, Ryu JC: Phospholipidosis induced by PPARgamma signaling in human bronchial epithelial (BEAS-2B) cells exposed to amiodarone. Toxicol Sci. 2011; 120(1): 98-108.
54. NIH StatPearls: Amiodarone. https://www.ncbi.nlm.nih.gov/books/NBK482154/